Phase I Clinical Study of Edaravone in Healthy Chinese Volunteers

Hao Li, Kun Xu, Yongqing Wang, Hongwen Zhang, Tianping Li, Ling Meng, Xiaojian Gong, Haibo Zhang, Ning Ou, Jinman RuanDrugs 2012 · DOI

Abstract

This study investigated the safety and pharmacokinetics (PK) of edaravone administered via single or successive intravenous infusions in 30 healthy Chinese volunteers. Subjects were randomized into three groups receiving 20, 30, or 60 mg doses. All participants received a single 30-minute infusion; the 30 mg group continued with twice-daily infusions for five days. Plasma concentrations were monitored using high-performance liquid chromatography (HPLC). The study found that $C_{max}$ and $AUC_{\tau}$ values increased linearly with the dose. For single doses of 20, 30, and 60 mg, $AUC_{\tau}$ values were $3.64 \pm 1.37$, $5.17 \pm 0.93$, and $11.25 \pm 3.42$ mg·h/L, respectively. Repeated dosing of 30 mg showed no significant accumulation, with a mean $AUC_{\tau}$ of $5.06 \pm 0.89$ mg·h/L. Edaravone was safe and well-tolerated, with only mild, transient laboratory abnormalities observed.

What Problem Does This Paper Address?

Ischemic stroke triggers a biochemical cascade where reperfusion leads to the overproduction of free radicals, such as hydroxyl and peroxynitrite radicals, causing extensive oxidative damage to brain tissue. Edaravone is a potent free-radical scavenger designed to mitigate this damage.

While edaravone is used clinically, PK profiles can vary significantly across ethnic populations due to genetic and physiological differences. This study addresses the need for specific Phase I data in a Chinese cohort to determine how the drug is absorbed, distributed, and eliminated, and to establish safe dosing limits for single and repeated intravenous administrations.

Methods

The researchers conducted a randomized, open-label study involving 30 healthy Chinese volunteers (15 men and 15 women).

  • Dosing Regimen: Participants were split into three dose groups: 20 mg, 30 mg, and 60 mg. All subjects received a single 30-minute intravenous infusion. To study repeated exposure, the 30 mg group continued receiving the dose twice daily for five additional days.
  • Analytical Technique: The team developed a simplified HPLC method with an ultraviolet (UV) detector. They optimized the extraction process to take less than 10 minutes, minimizing the degradation of edaravone, which is notoriously unstable in human plasma.
  • Statistical Analysis: PK parameters like the Area Under the Curve ($AUC$) and maximum plasma concentration ($C_{max}$) were calculated using noncompartmental analysis via DAS 2.0 software.

Datasets

The dataset consists of physiological and biochemical measurements from the 30 recruited healthy volunteers. Demographics including age, weight, height, and BMI were meticulously tracked to ensure a representative sample for the Phase I trial.

Demographic characteristics of the healthy Chinese volunteers

Safety monitoring included 12-lead ECGs, physical examinations, and a comprehensive battery of laboratory tests (hematology, urinalysis, and blood chemistry) performed before and after drug administration.

Key Insights and Ideas

  • Linear Pharmacokinetics: The study demonstrated a strong linear correlation between the dose (20–60 mg) and both $C_{max}$ and $AUC$. This predictable relationship simplifies clinical dosing strategies.
  • Zero Accumulation: A critical finding for safety was the lack of drug buildup. The ratio of $AUC$ and $C_{max}$ between the first day and the fifth day of repeated dosing was approximately 1.0, indicating that the body clears edaravone efficiently between twice-daily doses.
  • Stability Sensitivity: The authors highlighted that edaravone's instability in air-exposed plasma often leads to underreported $C_{max}$ values. Their rapid 10-minute extraction method likely provided more accurate peak concentration data than previous studies with longer processing times.

Key Results

The pharmacokinetic analysis confirmed that edaravone follows a linear model within the tested dose range. The plasma concentration-time profiles show distinct peaks corresponding to the dose levels, with the 30 mg single and repeated dose curves overlapping almost perfectly, confirming the lack of accumulation.

Plasma edaravone concentration-time profiles for single and repeated doses
  • Peak Concentrations: $C_{max}$ values reached $1599.0 \pm 382.6$, $2378.7 \pm 316.7$, and $4540.1 \pm 901.1$ ng/mL for the 20, 30, and 60 mg doses, respectively.
  • Safety Profile: The drug was well-tolerated. Observed laboratory abnormalities—such as mild increases in alanine transaminase (ALT) and triacylglycerol—were transient and returned to baseline within seven days without medical intervention.

Limitations and Future Work

The primary limitation is that the study was conducted on healthy volunteers. The PK profile and safety may differ in elderly stroke patients who often present with comorbidities like impaired renal or hepatic function. Additionally, while the study confirms metabolism via sulfation and glucuronidation, it does not explore specific metabolic pathways or potential drug-drug interactions in detail. Future research should investigate these factors in clinical patient populations over longer treatment windows.

Summary updated

Abstract

The objective of this study was to investigate the safety and pharmacokinetics of edaravone administered by single or successive intravenous infusions in healthy Chinese volunteers. A total of 30 subjects (15 males and 15 females) were recruited and randomly assigned to three groups receiving edaravone doses of 20, 30, and 60 mg. All subjects received a single dose of edaravone during a 30-minute period, and only the 30 mg dose group continued to receive the same dose successively by intravenous infusion twice daily for the next 5 days. Plasma concentrations of edaravone were monitored by high-performance liquid chromatography at the following times: 15, 30, 45, 60, 75, 105, 165, 225, 300, 390, 480, 600, and 720 minutes after edaravone administration. The area under the plasma concentration-time curve during a dosage interval (AUCτ) values of the single dose in the 20, 30, and 60 mg dose groups were 3.64±1.37, 5.17 ± 0.93, and 11.25 ± 3.42 mg · h/L, respectively, while in the group receiving repeated dosing of 30 mg, the mean AUCτ value was 5.06 ± 0.89mg · h/L. The corresponding maximum plasma drug concentration (Cmax) values were 1599.0 ± 382.6, 2378.7 ± 316.7, and 4540.1 ± 901.1 ng/mL, respectively, in the single-dose groups, and 2479.1 ± 477.9 ng/mL in the 30 mg repeated-dose group. The mean AUCτ and Cmax ratios between the repeated-dose group and the single-dose groups were 0.98 and 1.04. All laboratory test abnormalities (including increased alanine transaminase and triacylglycerol levels, and decreased white blood cell counts and creatinine levels) were mild and tolerable. All abnormal blood biochemical indices returned to normal levels after 7 days. Edaravone was safe and well tolerated in the volunteers and displayed linear increases in the Cmax and AUCτ values.
BibTeX
@inproceedings{li2012phase,
  author = {Hao Li and Kun Xu and Yongqing Wang and Hongwen Zhang and Tianping Li and Ling Meng and Xiaojian Gong and Haibo Zhang and Ning Ou and Jinman Ruan},
  title = {{Phase I Clinical Study of Edaravone in Healthy Chinese Volunteers}},
  booktitle = {Drugs},
  year = {2012},
  doi = {10.1007/bf03262192},
}
Figure